News &
Events
CORPORATE ANNOUNCEMENTS & PORTFOLIO UPDATES
Featured Article
Solaris Pharma Corporation located in Bridgewater, New Jersey announces final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clobetasol Propionate Cream USP, 0.05% in the following packaging configurations, 15 g, 30 g, 45 g and 60 g tubes. For more updates, please feel free to email us info@solaris-pharma.com
Solaris launches generic Briviact
Solaris has announced the launch of brivaracetam tablets, a generic version of UCB’s branded epilepsy medication Briviact.
The
Solaris Pharma Receives FDA Approval for Tazarotene Gel, 0.05% and 0.1%
Solaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.
Solaris Pharma Receives FDA Approval for First Generic Clindamycin Phosphate Topical Gel, 1%
BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) — Solaris Pharma Corporation (“Solaris” or the “Company”) announced today that the
Solaris Pharma Receives FDA Approval for Clindamycin Phosphate Gel USP, 1% (Once-A-Day)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Oil, 0.01% (Ear Drops)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its